NCT02905318 2026-03-09
Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer
Canadian Cancer Trials Group
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT03297606 2026-03-04
CAPTUR
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT02630693 2025-11-25
Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT03644186 2024-12-13
TOUCH
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT02536742 2024-02-26
PYTHIA
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT03088059 2023-11-03
UPSTREAM
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Unknown
NCT02154490 2023-06-01
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
SWOG Cancer Research Network
Completed
NCT03628066 2022-04-20
Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer
NSABP Foundation Inc
Phase 2 Completed
NCT02296801 2022-01-13
PALLET
NSABP Foundation Inc
Phase 2 Completed
NCT02255461 2021-03-02
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Pediatric Brain Tumor Consortium
Phase 1 Terminated